Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Clinical Trials

SCALOP-2: Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2

SCALOP2 logoLocally advanced non-metastatic pancreatic cancer is usually treated with chemoradiotherapy. However, the treatment is not very effective, usually only controlling symptoms and slowing tumour growth.

This registered multi-centre open-label study will test whether increasing the radiotherapy dose and adding nelfinavir to the chemoradiotherapy will improve the outcome of patients with inoperable pancreatic cancer that has not spread beyond the pancreas.

This trial is run by OCTO.

Sharon Love and Pradeep Virdee

SPARC: Stereotactic Body Radiotherapy (SBRT) pre-operatively for borderline resectable pancreatic cancer

Radiotherapy is often used to shrink a tumour before surgery, to make it easier to remove fully. Stereotactic body radiation therapy (SBRT) directs radiotherapy beams at the cancer from different positions around the body. It delivers a high dose of treatment to the cancer, leaving the surrounding tissue relatively unaffected.

SPARC is a phase I trial that will test whether pre-operative doses of SBRT can shrink previously untreated borderline resectable pancreatic cancer tumours enough for them to be surgically removed.

This trial is run by OCTO.

Vicky Strauss